Research programme: GPR119 protein agonists - Exelixis
Latest Information Update: 09 Mar 2011
At a glance
- Originator Exelixis
- Mechanism of Action GPR119 protein agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 22 Feb 2011 Discontinued for Metabolic disorders in USA (unspecified route)
- 12 Dec 2008 Early research in Metabolic disorders in USA (unspecified route)